Stella Pharma Corporation
Research Stella Pharma Corporation (4888.T) on Bullrun: market cap JPY 14.59B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4888.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 14.59B
- Financial periodFY2026
- RevenueJPY 323.39M
- Revenue growth-66.4%
- Net income-JPY 780.92M
- Free cash flow-JPY 346.17M
- Gross margin86.3%
Valuation Snapshot
latest market cap is JPY 14.59B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 323.39M | -JPY 780.92M | -JPY 346.17M | 86.3% | -22.95 | JPY 2.82B | JPY 747.14M | JPY 2.43B |
| FY2025 | JPY 961.06M | -JPY 140.81M | JPY 128.00M | 88.0% | -4.22 | JPY 3.21B | JPY 766.78M | JPY 3.21B |
| FY2024 | JPY 269.49M | -JPY 763.75M | -JPY 887.82M | 80.6% | -24.66 | JPY 2.05B | JPY 933.30M | JPY 2.38B |
| FY2023 | JPY 229.07M | -JPY 778.82M | -JPY 857.00M | 90.3% | -26.97 | JPY 2.71B | JPY 1.09B | JPY 2.75B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 14.59B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Stella Pharma Corporation
Stella Pharma Corporation engages in research and development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its products include SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma and angiosarcoma, glioblastoma, and thoracic malignant tumor. Stella Pharma Corporation was incorporated in 2007 and is headquartered in Osaka, Japan.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Stella Pharma Corporation's market cap?
Stella Pharma Corporation's market capitalization is JPY 14.59B.
What does Stella Pharma Corporation do?
Stella Pharma Corporation engages in research and development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its products include SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma and angiosarcoma, glioblastoma, and thoracic malignant tumor. Stella Pharma Corporation was incorporated in 2007 and is headquartered in Osaka, Japan.